(Q38841182)

6 September 2017

Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease (English)

1 reference

6 September 2017

0 references

11

1 reference

6 September 2017

13

1 reference

6 September 2017

Claudia Fabiani

4

0 references

Giacomo Emmi

object named as

Giacomo Emmi

2

0 references

Mauro Galeazzi

10

object named as

Mauro Galeazzi

1 reference

6 September 2017

8

Florenzo Iannone

1 reference

6 September 2017

3

Giuseppe Lopalco

1 reference

6 September 2017

6

Elena Silvestri

1 reference

6 September 2017

12

Donato Rigante

1 reference

6 September 2017

9

Bruno Frediani

1 reference

6 September 2017

Antonio Vitale

1

1 reference

6 September 2017

Stefano Gentileschi

5

1 reference

6 September 2017

Di Scala Gerardo

7

1 reference

6 September 2017

language of work or name

1 reference

11 April 2017

1 reference

6 September 2017

Clinical Rheumatology

1 reference

Behçet's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions.

6 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Cross-cultural adaptation of the Behçet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

EULAR recommendations for the management of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

New therapeutic solutions for Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Safety and efficacy of etanercept in children with juvenile-onset Behcets disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Etanercept therapy in Behçet's disease. The tight control strategy in refractory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Behçet Disease-associated Uveitis Successfully Treated with Golimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Anakinra treatment in drug-resistant Behcet’s disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-017-3627-4

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

21 January 2018

1 reference

12 December 2020

Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

1 reference

12 December 2020

Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease

1 reference

12 December 2020

The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.

1 reference

12 December 2020

Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab

1 reference

12 December 2020

Etanercept in the treatment of intestinal Behcet's disease

1 reference

12 December 2020

Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series

1 reference

12 December 2020

Behçet's syndrome: a critical digest of the 2014-2015 literature

1 reference

12 December 2020

A case of neuromyotonia in Behçet disease during TNF-α antagonist therapy

1 reference

12 December 2020

10.1007/S10067-017-3627-4

Identifiers

DOI

1 reference

release_xpxmjb7owjgflbcn74hst5i5am

6 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xpxmjb7owjgflbcn74hst5i5am

24 November 2022

mapped directly with Wikidata item

1 reference